FanZhi Medical Secures Over RMB 100 Million Series D Funding Led by Jianchuang Healthcare Growth Fund, with Co-Lead Investors GSR Ventures and Zhilai Capital

Recently, Beijing FanZhi Medical Technology Co., Ltd. (hereinafter referred to as “FanZhi Medical”) completed a Series D financing round exceeding RMB 100 million, led byJianchuang Medical Growth FundLead Investor,GoldenSand Capital、ZhiLai CapitalCo-led the investment round. The funds raised will be primarily used for the research, development, and iteration of various rapid testing instruments and multiplex diagnostic reagents, continuously optimizing the product portfolio and accelerating the application for medical device registration certificates. Additionally, the company will significantly expand existing production capacity, drive in-depth market deployment both domestically and internationally, and further achieve industrialization and economies of scale.

This round of financing marks another endorsement by top-tier renowned investors for FanZhi Medicine, following the completion of its C-round financing worth hundreds of millions of yuan in 2022. It reflects the capital market’s strong focus on the field of rapid disease diagnosis, as well as its full confidence in FanZhi Medicine’s team strength, technological accumulation, and product commercialization.

Fanzhi Medicine has accumulated profound underlying technologies for import substitution and innovated its business model. Multiple first-of-their-kind devices are currently in the registration phase. The company has completed seven rounds of financing, with investors including CCB Medical Growth Fund, Zhongguancun Science City Fund, Hairong Capital, Zhongguancun Open Fund, Skyworth Capital, Tianjin Government Fund, Shandong State-owned Assets, and GoldenSand Capital. Bolstered by capital support and its own development, Fanzhi Medicine possesses the potential to grow into a “unicorn” high-tech enterprise in the field of in vitro diagnostics.

Fanzhi Medicine is a global biopharmaceutical high-tech enterprise founded by senior scientists from the Chinese Academy of Sciences, overseas-returnee scientists, and clinical experts. Committed to independent research and development, it has built an internationally advanced brand for rapid disease diagnosis and treatment. Fanzhi Medicine provides integrated solutions encompassing testing instruments, chips, diagnostic reagents, and internet-based remote diagnosis and treatment products and services, making it one of the few companies in the industry with a full industrial chain layout.

The core team comprises scientists, clinical experts, and executives from world-leading institutions, pharmaceutical companies, and hospitals, including the Chinese Academy of Sciences, Tsinghua University, Peking University, Harvard University, the University of Kansas, Columbia University, Merck & Co., Pfizer, and PLA General Hospital (301 Hospital).

Over the past seven years, FanZhi Medicine has continuously strengthened its industrial chain layout and R&D investment, striving to overcome critical “chokepoint” technologies through independent innovation. The company now holds more than 150 authorized patents, facilitating a leapfrog development from import substitution to pioneering national first-of-its-kind innovations. It has received numerous honors, including recognition as a “Specialized, Refined, Differential, and Innovative” (SRDI) enterprise, a “Gazelle Enterprise,” and one of the “Top 100 Chinese Sci-Tech Innovation Enterprises in 2020.”

Fan Zhi Medicine has successively resolved issues such as the miniaturization and intelligent integration of diagnostic instruments, the localization of core key raw materials, and the development of integrated rapid detection chips, making it one of the few companies in China’s rapid disease diagnosis and treatment sector withCore Technical Development Capabilities in Nucleic Acids, Chips, Mechanics, and Software...the company has also achieved differentiated advantages across multiple touchpoints in the competition among international brands.Since its inception, Fanzhi Medicine has obtained regulatory approvals from the U.S. FDA, the EU CE, and China's NMPA for dozens of product pipelines, entering more than 30 countries and regions.

Fanzhi Medicine boasts a comprehensive global system encompassing R&D, manufacturing, and marketing. Its headquarters’ R&D center is located in Haidian District, Beijing, with large-scale GMP-compliant facilities, R&D and production sub-centers, or branches established in Jiangsu, Shandong, Zhejiang, and other regions. The company complies with the registration and quality management system standards of China’s NMPA, the EU’s CE, and the US FDA, achieving a closed-loop service model integrating production, academia, research, sales, and inspection.

In clinical applications, FanZhi Medicine has launched a range of rapid testing devices, chips, and reagents, enabling precise and rapid “sample-in, result-out” detection. This initiative facilitates the integration of rapid disease diagnosis and treatment into China’s grassroots healthcare system, extending to hospitals, health examination centers, communities, households, and quarantine markets, thereby addressing the healthcare reform challenges of difficult and costly access to medical care at the local level.

Fanzhi Medicine has established a mature market network, with branches or offices in Beijing, Hong Kong, Tianjin, Shanghai, Jinan, Guangzhou, Nanjing, Wuhan, Xi’an, and other cities. It pioneered a global three-tier internet marketing system and is driven by the dual engines of R&D capability and market strength. During its rapid growth phase, Fanzhi Medicine forged long-term, stable partnerships with numerous renowned enterprises and clinical institutions, including Fosun Pharma, Hengrui Medicine, WuXi AppTec, Genetron Health, Peking Union Medical College Hospital, and the Chinese PLA General Hospital (301 Hospital).

Furthermore, FanZhi Medicine has distributors in over 30 countries overseas, providing products and services to thousands of hospitals, pharmaceutical companies, research institutes, genetic testing companies, communities, and households worldwide.Overseas revenue accounts for more than one-third, achieving a dual circulation of domestic and international markets, with operating income maintaining rapid growth.

By leveraging its years of deep cultivation in foundational technologies, resource coordination, and equity-based partnerships, Fanzhi Medicine has spearheaded the creation of Fanzhi Cloud Chain, a leading industrial-grade biopharmaceutical ecosystem platform in China, which brings together dozens of upstream and downstream enterprises across the pharmaceutical supply chain.

Through deep collaborative synergies with ecosystem partners specializing in protein antibody raw materials, instruments, chips, diagnostic reagents, pathogenic microorganism sequencing, single-cell sequencing, gene editing, and early cancer screening, FanZhi Cloud Chain has strengthened its control over supply and ecosystem chains, established differentiated international competitive advantages through consortium-based strategies, and facilitated the development of China’s biomedical industry ecosystem. As the leading enterprise of the “FanZhi Cloud Chain” pharmaceutical ecosystem, FanZhi Medicine will continue to contribute to promoting the high-quality development of the national biomedical industry ecosystem.

Dr. Song Keqing, Founder of Fan Zhi Medicinestated, “We extend our sincere gratitude to the leading-tier funds for their strong empowerment. With this round of financing, the company will accelerate the R&D and regulatory registration of multiple innovative products, continuously expand multi-scenario applications, and enhance the operational capabilities of individual products, thereby building comprehensive advantages in product offerings, distribution channels, and brand presence through a whole-industry-chain layout. We remain committed to our original mission of ‘bringing rapid diagnostic and treatment technologies for major diseases into primary healthcare systems, enabling broader access to convenient medical services for the general public,’ aiming to achieve comprehensive coverage across thousands of cities and townships, empower more healthcare institutions, and contribute to the Healthy China initiative.”

Jianchuang Medical Growth Fund is a new-phase healthcare industry fund established in Liandu District, Lishui City. The team possesses extensive experience in fund management and industry investment research, with a focus on equity investments in the medical and healthcare sector. Leveraging the resource advantages, favorable business environment, and robust policy support of Liandu District, Lishui City, the fund covers investment stages from angel rounds to pre-IPO. Its primary investment areas include innovative drugs, innovative medical devices, and in vitro diagnostics (IVD). The fund aims to establish a comprehensive, multi-regional industrial layout across all development stages, while also empowering portfolio companies to facilitate their growth.

GoldenSand Capital focuses on investing in high-tech enterprises based in China and oriented toward the global market. Whether in China or Silicon Valley, USA, GoldenSand Capital has established extensive relationships and possesses abundant resources to provide strong support for its portfolio companies. The firm’s investments span biopharmaceuticals, semiconductors and new materials, internet and wireless communication technologies and their applications, green energy, and other high-growth emerging sectors.

Beijing ZhiLai Investment Management Co., Ltd. (hereinafter referred to as “ZhiLai Investment”), established in Beijing in 2017, is a private equity investment firm co-founded by a team of professionals from renowned private equity firms, banks, securities companies, guarantee institutions, and law firms. Guided by the corporate culture of “Integrity, Wisdom, Serenity, and Benevolence,” the company is committed to its mission of “advancing China’s modernization through industrial investment” and envisions becoming “a globally influential private equity investment institution.” ZhiLai Investment pioneered in China a market-oriented industrial fund model that conducts private equity investments through private equity funds. Currently, it manages multiple industrial investment fund-of-funds and subsidiary funds, with investments spanning “deep tech” and “hard tech” sectors such as new materials, new energy, electronic information, gene technology, intelligent manufacturing, electric/connected/autonomous vehicles, and aerospace.